| Clinical data | |
|---|---|
| Other names | AMG 133 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
MariTide, also known as maridebart cafraglutide[1] (developmental name AMG 133), is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor and an antagonist of the GIPR. In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.[2][3][4]
References
- ^ Beasley, Deena (2024-02-06). "Amgen taking different path to weight loss windfall". Reuters. Retrieved 2024-03-06.
- ^ Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.
- ^ Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.
- ^ Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 2 June 2024, at 18:40